Anavex Life Sciences Corp (AVXL)

[Investor2014]

EMA accepts an MAA on being complete with valid contents. That does not make the data contained 'sufficient' for approval. If it did then why have a long deep review after with clock stop questions.

Refer to one of my prevision posts and this conclusion.

Conclusion: Does the Overall EMA Approval Rate Provide a Good Estimate?
While overall EMA approval rates (e.g., 85% of accepted filings) are encouraging, they cannot accurately predict Anavex’s chances because:

The complexity and high-stakes nature of AD make approval more challenging.
Averages do not reflect the individual strengths or weaknesses of a specific submission.
A valid estimate requires detailed consideration of Anavex’s clinical trial data, the regulatory landscape for AD, and historical approval patterns for similar therapies. Until detailed EMA feedback is available, only a cautious optimism based on the strength of submitted data is warranted.